WO2003049741A1 - Ureas of 2-aminobenzothiazoles as adenosine modulators - Google Patents

Ureas of 2-aminobenzothiazoles as adenosine modulators Download PDF

Info

Publication number
WO2003049741A1
WO2003049741A1 PCT/EP2002/013761 EP0213761W WO03049741A1 WO 2003049741 A1 WO2003049741 A1 WO 2003049741A1 EP 0213761 W EP0213761 W EP 0213761W WO 03049741 A1 WO03049741 A1 WO 03049741A1
Authority
WO
WIPO (PCT)
Prior art keywords
methoxy
benzothiazol
morpholin
aza
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/013761
Other languages
English (en)
French (fr)
Inventor
Alexander Flohr
Roland Jakob-Roetne
Roger David Norcross
Claus Riemer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to JP2003550790A priority Critical patent/JP4245483B2/ja
Priority to BR0214825-0A priority patent/BR0214825A/pt
Priority to MXPA04005444A priority patent/MXPA04005444A/es
Priority to KR1020047008868A priority patent/KR100659793B1/ko
Priority to AU2002356626A priority patent/AU2002356626B2/en
Priority to EP02804578A priority patent/EP1455792B1/en
Priority to ES02804578T priority patent/ES2283652T3/es
Priority to DE60219682T priority patent/DE60219682T2/de
Priority to CA002469596A priority patent/CA2469596A1/en
Publication of WO2003049741A1 publication Critical patent/WO2003049741A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Definitions

  • Preferred compounds ofthe present application for use against diseases, related to the A 2a receptor are compounds of formula I, wherein X is -O-, for example the following compounds:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PCT/EP2002/013761 2001-12-10 2002-12-05 Ureas of 2-aminobenzothiazoles as adenosine modulators Ceased WO2003049741A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2003550790A JP4245483B2 (ja) 2001-12-10 2002-12-05 アデノシン調節薬としての２−アミノベンゾチアゾールの尿素
BR0214825-0A BR0214825A (pt) 2001-12-10 2002-12-05 Uréias de 2-aminobenzotiazóis como moduladores de adenosina
MXPA04005444A MXPA04005444A (es) 2001-12-10 2002-12-05 Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
KR1020047008868A KR100659793B1 (ko) 2001-12-10 2002-12-05 아데노신 조절제로서의 2-아미노벤조티아졸의 유레아
AU2002356626A AU2002356626B2 (en) 2001-12-10 2002-12-05 Ureas of 2-aminobenzothiazoles as adenosine modulators
EP02804578A EP1455792B1 (en) 2001-12-10 2002-12-05 Ureas of 2-aminobenzothiazoles as adenosine modulators
ES02804578T ES2283652T3 (es) 2001-12-10 2002-12-05 Ureas de 2-aminobenzotiazoles como modulares de adenosina.
DE60219682T DE60219682T2 (de) 2001-12-10 2002-12-05 Harnstoffe von 1-Aminobenzothiazolen als Adenosin-Modulatoren
CA002469596A CA2469596A1 (en) 2001-12-10 2002-12-05 Ureas of 2-aminobenzothiazoles as adenosine modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01129228.1 2001-12-10
EP01129228 2001-12-10

Publications (1)

Publication Number Publication Date
WO2003049741A1 true WO2003049741A1 (en) 2003-06-19

Family

ID=8179478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/013761 Ceased WO2003049741A1 (en) 2001-12-10 2002-12-05 Ureas of 2-aminobenzothiazoles as adenosine modulators

Country Status (20)

Country Link
US (2) US6727247B2 (cg-RX-API-DMAC7.html)
EP (1) EP1455792B1 (cg-RX-API-DMAC7.html)
JP (1) JP4245483B2 (cg-RX-API-DMAC7.html)
KR (1) KR100659793B1 (cg-RX-API-DMAC7.html)
CN (1) CN1602196A (cg-RX-API-DMAC7.html)
AR (1) AR037731A1 (cg-RX-API-DMAC7.html)
AT (1) ATE359792T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002356626B2 (cg-RX-API-DMAC7.html)
BR (1) BR0214825A (cg-RX-API-DMAC7.html)
CA (1) CA2469596A1 (cg-RX-API-DMAC7.html)
DE (1) DE60219682T2 (cg-RX-API-DMAC7.html)
ES (1) ES2283652T3 (cg-RX-API-DMAC7.html)
GT (1) GT200200266A (cg-RX-API-DMAC7.html)
MX (1) MXPA04005444A (cg-RX-API-DMAC7.html)
PA (1) PA8559901A1 (cg-RX-API-DMAC7.html)
PE (1) PE20030759A1 (cg-RX-API-DMAC7.html)
PL (1) PL371063A1 (cg-RX-API-DMAC7.html)
RU (1) RU2311905C2 (cg-RX-API-DMAC7.html)
TW (1) TW200409628A (cg-RX-API-DMAC7.html)
WO (1) WO2003049741A1 (cg-RX-API-DMAC7.html)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105755A1 (en) * 2003-05-30 2004-12-09 F. Hoffmann-La Roche Ag Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor
WO2005000842A1 (en) * 2003-05-19 2005-01-06 F. Hoffman-La Roche Ag Benzothiazole derivatives as adenosine receptor ligands
WO2005028484A1 (en) * 2003-09-19 2005-03-31 F. Hoffmann-La Roche Ag Thiazolopyridine derivatives as adenosine receptor ligands
WO2005068463A1 (en) * 2004-01-08 2005-07-28 F. Hoffmann-La Roche Ag Diaza-spiropiperidine derivatives
WO2005116026A1 (en) * 2004-05-24 2005-12-08 F. Hoffmann-La Roche Ag 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
WO2006008040A1 (en) * 2004-07-22 2006-01-26 F. Hoffmann-La Roche Ag Substituted benzothiazoles
WO2006008041A1 (en) * 2004-07-22 2006-01-26 F. Hoffmann-La Roche Ag Benzothiazole derivatives
US7238808B2 (en) 2005-03-23 2007-07-03 Hoffmann-La Roche Inc. Acetylenyl-pyrazolo-pyrimidine derivatives
WO2007140439A3 (en) * 2006-05-31 2008-01-24 Abbott Lab Compounds as cannabinoid receptor ligands and uses thereof
KR100834179B1 (ko) * 2004-05-24 2008-05-30 에프. 호프만-라 로슈 아게 4-하이드록시-4-메틸-피페리딘-1-카복실산(4-메톡시-7-모폴린-4-일-벤조티아졸-2-일)-아마이드
US7504404B2 (en) 2005-09-27 2009-03-17 Hoffmann-La Roche Inc. Compounds as metabotropic glutamate receptor antagonists
US7714009B2 (en) 2003-10-31 2010-05-11 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
EP2065369A4 (en) * 2006-08-23 2011-12-28 Astellas Pharma Inc UREA CONNECTION OR SALT THEREOF
US8455520B2 (en) 2007-07-17 2013-06-04 Merck Sharp & Dohme Corp. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
EP1522314B1 (en) * 2002-06-26 2014-03-05 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
US8735434B2 (en) 2007-05-18 2014-05-27 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8835475B2 (en) 2007-04-17 2014-09-16 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
WO2014146994A1 (en) * 2013-03-20 2014-09-25 F. Hoffmann-La Roche Ag Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors
WO2014146995A1 (en) * 2013-03-20 2014-09-25 F. Hoffmann-La Roche Ag Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8859596B2 (en) 2008-09-16 2014-10-14 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8865753B2 (en) 2007-03-28 2014-10-21 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8895592B2 (en) 2008-12-16 2014-11-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8940745B2 (en) 2010-05-03 2015-01-27 Janssen Pharmaceutica Nv Modulators of fatty acid amide hydrolase
US9169224B2 (en) 2004-12-30 2015-10-27 Janssen Pharmaceutica Nv Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2251419C2 (ru) * 2000-06-21 2005-05-10 Ф. Хоффманн-Ля Рош Аг Производные бензотиазола
DE60216830T2 (de) * 2001-02-06 2007-06-14 Pfizer Products Inc., Groton Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
EP1622569B1 (en) 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
CA2655310A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
AR064561A1 (es) * 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
JP2010528114A (ja) * 2007-05-25 2010-08-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 脂肪酸アミド加水分解酵素のヘテロアリール置換尿素モジュレータ
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
FR2945531A1 (fr) * 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2010141809A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
WO2011021645A1 (ja) * 2009-08-19 2011-02-24 大日本住友製薬株式会社 ２環性ウレア誘導体、またはその薬学的に許容される塩
JP6483610B2 (ja) * 2012-07-18 2019-03-13 ユニバーシティ オブ ノートルダム デュ ラック ５，５−ヘテロ芳香族抗感染症化合物
EP3529245A4 (en) * 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THE LATEST
MA47212A (fr) 2017-01-06 2019-11-13 Yumanity Therapeutics Inc Méthodes de traitement de troubles neurologiques
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
WO2019141096A1 (zh) * 2018-01-19 2019-07-25 四川科伦博泰生物医药股份有限公司 取代脲类化合物及其制备方法和用途
ES3043183T3 (en) 2018-03-23 2025-11-25 Janssen Pharmaceutica Nv Compounds and uses thereof
CN111205244B (zh) * 2018-11-22 2023-08-18 上海科技大学 噻唑并环类化合物、其制备方法、中间体和应用
MA54829A (fr) 2019-01-24 2021-12-01 Yumanity Therapeutics Inc Composés et leurs utilisations
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057008A1 (en) * 2000-02-07 2001-08-09 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
WO2001097786A2 (en) * 2000-06-21 2001-12-27 F. Hoffmann-La Roche Ag Benzothiazole derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US45615A (en) * 1864-12-27 Improvement in cultivators
US3954766A (en) * 1975-07-09 1976-05-04 Stanford Research Institute 1,4-Diazabicyclo[3.2.1]octanes
DE3374550D1 (en) 1982-12-21 1987-12-23 Johnsen Jorgensen Plastics Ltd Dispensing container
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
US6599901B1 (en) * 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057008A1 (en) * 2000-02-07 2001-08-09 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
WO2001097786A2 (en) * 2000-06-21 2001-12-27 F. Hoffmann-La Roche Ag Benzothiazole derivatives

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765783B2 (en) * 2002-06-26 2014-07-01 Ono Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation
EP1522314B1 (en) * 2002-06-26 2014-03-05 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
WO2005000842A1 (en) * 2003-05-19 2005-01-06 F. Hoffman-La Roche Ag Benzothiazole derivatives as adenosine receptor ligands
US7371748B2 (en) 2003-05-19 2008-05-13 Hoffman-La Roche Inc. Benzothiazole derivatives
AU2004243481B2 (en) * 2003-05-30 2008-10-09 F. Hoffmann-La Roche Ag Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine A2A receptor
CN1798558B (zh) * 2003-05-30 2012-09-05 弗·哈夫曼-拉罗切有限公司 苯并噻唑衍生物和其在制备治疗与腺苷a2a受体有关的疾病的药物中的用途
WO2004105755A1 (en) * 2003-05-30 2004-12-09 F. Hoffmann-La Roche Ag Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor
US7285548B2 (en) 2003-05-30 2007-10-23 Hoffmann-La Roche Inc. Urea substituted benzothiazoles
WO2005028484A1 (en) * 2003-09-19 2005-03-31 F. Hoffmann-La Roche Ag Thiazolopyridine derivatives as adenosine receptor ligands
US7273865B2 (en) 2003-09-19 2007-09-25 Hoffmann-La Roche Inc. Thiazolopyridine
US7714009B2 (en) 2003-10-31 2010-05-11 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
WO2005068463A1 (en) * 2004-01-08 2005-07-28 F. Hoffmann-La Roche Ag Diaza-spiropiperidine derivatives
RU2355690C2 (ru) * 2004-01-08 2009-05-20 Ф.Хоффманн-Ля Рош Аг Производные диазаспиропиперидина
CN100413865C (zh) * 2004-01-08 2008-08-27 弗·哈夫曼-拉罗切有限公司 二氮杂-螺哌啶衍生物
US7173133B2 (en) 2004-01-08 2007-02-06 Hoffmann-La Roche Inc. Diaza-spiropiperidine derivatives
WO2005116026A1 (en) * 2004-05-24 2005-12-08 F. Hoffmann-La Roche Ag 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
US7368446B2 (en) 2004-05-24 2008-05-06 Hoffmann-La Roche Inc. 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
EA011279B1 (ru) * 2004-05-24 2009-02-27 Ф. Хоффманн-Ля Рош Аг (4-метокси-7-морфолин-4-илбензотиазол-2-ил)-амид 4-гидрокси-4-метилпиперидин-1-карбоновой кислоты
KR100834179B1 (ko) * 2004-05-24 2008-05-30 에프. 호프만-라 로슈 아게 4-하이드록시-4-메틸-피페리딘-1-카복실산(4-메톡시-7-모폴린-4-일-벤조티아졸-2-일)-아마이드
JP2008500295A (ja) * 2004-05-24 2008-01-10 エフ．ホフマン−ラ　ロシュ　アーゲー ４−ヒドロキシ−４−メチル−ピペリジン−１−カルボン酸（４−メトキシ−７−モルホリン−４−イル−ベンゾチアゾール−２−イル）−アミド
US7371749B2 (en) 2004-07-22 2008-05-13 Hoffmann-La Roche Inc. Benzothiazole derivatives
US7449461B2 (en) 2004-07-22 2008-11-11 Hoffmann-La Roche Inc. Benzathiazol-acetamides
AU2005263499B2 (en) * 2004-07-22 2010-11-25 F. Hoffmann-La Roche Ag Substituted benzothiazoles
WO2006008040A1 (en) * 2004-07-22 2006-01-26 F. Hoffmann-La Roche Ag Substituted benzothiazoles
WO2006008041A1 (en) * 2004-07-22 2006-01-26 F. Hoffmann-La Roche Ag Benzothiazole derivatives
US9169224B2 (en) 2004-12-30 2015-10-27 Janssen Pharmaceutica Nv Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
US7718661B2 (en) 2005-03-23 2010-05-18 Hoffmann-La Roche Inc. Acetylenyl-pyrazolo-pyrimidine derivatives
US8063048B2 (en) 2005-03-23 2011-11-22 Hoffmann-La Roche Inc. Acetylenyl-pyrazolo-pyrimidine derivatives
US7446113B2 (en) 2005-03-23 2008-11-04 Hoffman-La Roche Inc. Acetylenyl-pyrazolo-pyrimidine derivatives
US7238808B2 (en) 2005-03-23 2007-07-03 Hoffmann-La Roche Inc. Acetylenyl-pyrazolo-pyrimidine derivatives
US8093263B2 (en) 2005-09-27 2012-01-10 Hoffmann-La Roche Inc. Substituted pyrazolo [1,5-a] pyrimidines as metabotropic glutamate antagonists
US7504404B2 (en) 2005-09-27 2009-03-17 Hoffmann-La Roche Inc. Compounds as metabotropic glutamate receptor antagonists
US8349844B2 (en) 2005-09-27 2013-01-08 Hoffmann-La Roche Inc. Substituted pyrazolo [1,5-A] pyrimidines as metabotropic glutamate antagonists
US9006275B2 (en) 2006-05-31 2015-04-14 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
US7875639B2 (en) 2006-05-31 2011-01-25 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
WO2007140439A3 (en) * 2006-05-31 2008-01-24 Abbott Lab Compounds as cannabinoid receptor ligands and uses thereof
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
EP2065369A4 (en) * 2006-08-23 2011-12-28 Astellas Pharma Inc UREA CONNECTION OR SALT THEREOF
US8865753B2 (en) 2007-03-28 2014-10-21 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8835475B2 (en) 2007-04-17 2014-09-16 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8735434B2 (en) 2007-05-18 2014-05-27 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8455520B2 (en) 2007-07-17 2013-06-04 Merck Sharp & Dohme Corp. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8859596B2 (en) 2008-09-16 2014-10-14 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8895592B2 (en) 2008-12-16 2014-11-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8940745B2 (en) 2010-05-03 2015-01-27 Janssen Pharmaceutica Nv Modulators of fatty acid amide hydrolase
US9688664B2 (en) 2010-05-03 2017-06-27 Janssen Pharmaceutica Nv Modulators of fatty acid amide hydrolase
WO2014146995A1 (en) * 2013-03-20 2014-09-25 F. Hoffmann-La Roche Ag Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors
WO2014146994A1 (en) * 2013-03-20 2014-09-25 F. Hoffmann-La Roche Ag Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors
JP2016514106A (ja) * 2013-03-20 2016-05-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 尿素誘導体及びその脂肪酸結合タンパク質（ｆａｂｐ）阻害剤としての使用
US9708340B2 (en) 2013-03-20 2017-07-18 Hoffmann-La Roche Inc. Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors

Also Published As

Publication number Publication date
JP4245483B2 (ja) 2009-03-25
AU2002356626B2 (en) 2007-11-29
JP2005516006A (ja) 2005-06-02
EP1455792A1 (en) 2004-09-15
RU2311905C2 (ru) 2007-12-10
US7019001B2 (en) 2006-03-28
BR0214825A (pt) 2004-09-14
KR20040065576A (ko) 2004-07-22
KR100659793B1 (ko) 2006-12-19
ES2283652T3 (es) 2007-11-01
US20030149036A1 (en) 2003-08-07
GT200200266A (es) 2003-07-03
US6727247B2 (en) 2004-04-27
PL371063A1 (en) 2005-06-13
RU2004121166A (ru) 2005-05-10
CN1602196A (zh) 2005-03-30
MXPA04005444A (es) 2004-10-11
US20040229893A1 (en) 2004-11-18
PE20030759A1 (es) 2003-09-05
ATE359792T1 (de) 2007-05-15
AR037731A1 (es) 2004-12-01
TW200409628A (en) 2004-06-16
AU2002356626A1 (en) 2003-06-23
DE60219682T2 (de) 2008-01-17
PA8559901A1 (es) 2003-09-05
DE60219682D1 (de) 2007-05-31
EP1455792B1 (en) 2007-04-18
CA2469596A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
US6727247B2 (en) Substituted benzothiazole amide derivatives
US6713499B2 (en) 7-Amino-benzothiazole derivatives
US6734179B2 (en) Benzothiazoles
EP1636223B1 (en) Benzothiazole derivatives as adenosine receptor ligands
US6872833B2 (en) Adenosine receptor ligands
ZA200509608B (en) Benzothiazole derivatives and use thereof in the treatment of disease related to the adenosine A2A receptor
HK1092469B (en) Benzothiazole derivatives as adenosine receptor ligands

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002356626

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002804578

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/005444

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2469596

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020047008868

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20028246543

Country of ref document: CN

Ref document number: 2003550790

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004121166

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2002804578

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002804578

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2002356626

Country of ref document: AU

Date of ref document: 20021205

Kind code of ref document: B